Clinical trials: sponsored by Fox Chase Cancer Center
Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual…
- Conditions
- Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- INSITE (NCT06396533)
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Fox Chase Cancer Center
Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach
Adaptive Radiation for Abdominopelvic Metastases
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no…
- Trial name
- NCT05880667
- Testing
- Adaptive Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fox Chase Cancer Center
Oropharynx Cancer
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to…
- Trial name
- NCT05800574
- Testing
- Radiation therapy (5 days for 7 weeks), Radiation therapy (5 days for 6 weeks), Cisplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer, Urothelial Carcinoma
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
- Trial name
- RETAIN-3 (NCT07908979)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Fox Chase Cancer Center
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
- Trial name
- NCT06984562
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Pancreatic Cancer
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
This is a multi- centered two-stage Pilot Study assessing the tolerability and toxicity of an alternating regimen of FOLFOX and FOLFIRI for the treatment of newly diagnosed and untreated metastatic pancreatic cancer in patients…
- Trial name
- NCT05360732
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fox Chase Cancer Center
Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC)
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients…
- Conditions
- Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy
- Trial name
- NCT07167446
- Testing
- Cannabidiol (CBD), oxaliplatin-based chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer (Adenocarcinoma)
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
- Trial name
- DE-CART (NCT07219303)
- Testing
- adaptive stereotactic body radiation therapy (SBRT) with a SIB
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fox Chase Cancer Center
Cancer
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed…
- Trial name
- eReach2 (NCT05427240)
- Testing
- Pre-Test Intervention, Standard of Care, Post-Test Intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Endometrial Cancer
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and…
- Trial name
- NCT03099499
- Testing
- ONC201
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Fox Chase Cancer Center
Non Small Cell Lung Cancer
Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer
This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging.
- Trial name
- NCT07854769
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Genetic Disease, Cancer
Penn Medicine Biobank Return of Results Program
The goal of this hybrid type 1 effectiveness-implementation study is to evaluate and compare different ways of delivering genetic research results to participants.
- Conditions
- Genetic Disease, Cancer, Cardiovascular Diseases
- Trial name
- ROR (NCT06089954)
- Testing
- private web-portal eHealth disclosure of genetic results, eHealth education intervention (web or chatbot)
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lymphoma, Advanced Solid Tumor
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor…
- Trial name
- NCT04827810
- Testing
- Gamitrinib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Fox Chase Cancer Center
Gastric Cancer, Gastrointestinal Cancer
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation…
- Conditions
- Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
- Trial name
- NCT05274048
- Testing
- Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Fox Chase Cancer Center
Urothelial Carcinoma
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
A prospective, investigational study to assess the accuracy of standardized cystoscopic evaluation with tissue sampling performed immediately prior to definitive radical cystectomy to predict pathologic tumor stage and identify…
- Trial name
- NCT02968732
- Testing
- Radical Cystectomy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Fox Chase Cancer Center
Muscle-Invasive Bladder Carcinoma
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC).
- Trial name
- NCT04506554
- Testing
- AMVAC + Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Fox Chase Cancer Center
Surgery, Cancer
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).
- Trial name
- NCT05454280
- Testing
- Intensified post-discharge surveillance, Standard post-discharge surveillance
- Where
- United States
- Volunteers
- 526 people
- Sponsor
- Fox Chase Cancer Center
Care Delivery, Geriatrics
Understanding the Preferences and Views of Older Adults on the Use of Geriatric and Objective Functional Assessments for Cancer Treatment Planning.
This Interventional clinical study aims to explore how receiving information about their health and physical abilities affects the treatment decisions of older adults.
- Conditions
- Care Delivery, Geriatrics, Geriatric Assessment
- Trial name
- NCT06652347
- Testing
- Cancer care delivery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer, Colo-rectal Cancer
Prehabilitation in High-risk Oncologic Surgery
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07638410
- Testing
- Multidisciplinary Prehabilitation Program
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Fox Chase Cancer Center
Urothelial Carcinoma
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and…
- Trial name
- NCT07043972
- Testing
- Gemcitabine, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Fox Chase Cancer Center